A Multi-center, Randomized, Open-label, Controlled, One-year Trial to Measure the Effect of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteopenia and Osteoporosis
A Multi-center, Randomized, Open-label, Controlled, One-year Trial to Measure the Effect of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteopenia and Osteoporosis
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
Inclusion Criteria:
- Low bone mineral density (as indicated by a "t-score" of -2.0 or lower) postmenopausal women
Exclusion Criteria:
- Previous use of oral and iv bisphosphonates, parathormone, strontium ranelate, sodium fluoride.
Other protocol-defined inclusion/exclusion criteria applied to the study.
Multiple Cities, Germany